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Abstract
Background Between February and April 2020, Italy experienced an overwhelming growth of the COVID-19 pandemic. 
Little is known, at the country level, where and how patients on renal replacement therapy (RRT) have been mostly affected.
Methods Survey of the network of Nephrology centers using a simplified 17 items electronic questionnaire designed by 
Italian Society of Nephrology COVID-19 Research Group. We used spatial epidemiology and geographical information 
systems to map SARS-CoV-2 spread among RRT patients in Italy.
Results On April 9th 2020, all nephrology centers (n = 454) listed in the DialMap database were invited to complete the 
electronic questionnaire. Within 11 days on average, 365 centers responded (80.4% response rate; 2.3% margin of error) 
totaling 60,441 RRT patients. The surveyed RRT population included 30,821 hemodialysis (HD), 4139 peritoneal dialysis 
(PD), and 25,481 transplanted (Tx) patients respectively. The proportion of SARS-CoV-2 positive RRT patients in Italy 
was 2.26% (95% CI 2.14–2.39) with significant differences according to treatment modality (p < 0.001). The proportion of 
patients positive for SARS-CoV-2 was significantly higher in HD (3.55% [95% CI 3.34–3.76]) than PD (1.38% [95% CI 
1.04–1.78] and Tx (0.86% [95% CI 0.75–0.98]) (p < 0.001), with substantial heterogeneity across regions and along the 
latitude gradient (p < 0.001). In RRT patients the highest rate was in the north-west (4.39% [95% CI 4.11–4.68], followed 
by the north-east (IR 2.06% [1.79–2.36]), the center (0.91% [0.75–1.09]), the main islands (0.67% [0.47–0.93]), and the 
south (0.59% [0.45–0.75]. During the COVID-19 pandemic, among SARS-Cov-2 positive RRT patients the fatality rate was 
32.8%, as compared to 13.3% observed in the Italian population as of April 23rd.
Conclusions A substantial proportion of the 60,441 surveyed RRT patients in Italy were SARS-Cov-2 positive and sub-
sequently died during the exponential phase of COVID-19 pandemic. Infection risk and rates seems to differ substantially 
across regions, along geographical latitude, and by treatment modality.
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Introduction
Italy was among the countries most severely affected by 
COVID-19 pandemic [1–3], with an unprecedented and 
overwhelming growth of active cases and mortality, one 
of the highest in the world [4]. The first Italian patient 
with COVID-19 was confirmed on February 21st, 2020 at 
Codogno Hospital in Lombardy. By early March, the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection had spread rapidly, yet heterogeneously, through-
out the country. A substantial latitude gradient had been 
reported, with the highest spread in the Northern regions and 
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the lowest in the Southern regions and in the main Islands 
[5].
The relationship between SARS-CoV-2 infection 
and comorbidity is complex, multifaceted, and further 
complicated by an unknown number of asymptomatic 
cases [6]. Nonetheless, severe and deadly cases are most 
often reported in elderly patients, especially in those with 
comorbidities [7]. Patients with renal failure are often old 
and with major comorbidities, thus at increased risk for 
COVID-19 morbidity and mortality [8, 9]. Additionally, they 
often have high levels of contact with health-care facilities 
and providers for dialysis sessions, clinical monitoring, 
and supportive care. According to a recent report of the 
Italian National Institute of Health (Istituto Superiore di 
Sanità [ISS]), among the most common comorbidities of 
COVID-19 patients dying in Italy, chronic kidney disease 
and dialysis are found in 21% and 2% of deceased patients 
respectively [10].
In Italy, preliminary studies confirmed that patients 
on renal replacement therapy (RRT), especially those on 
hemodialysis (HD), are particularly vulnerable for severe 
and fatal COVID-19 [11–15]. Thus far, while several reports 
and editorials focused on this fragile population [8, 11–15], 
no large-scale country level study addressed the COVID-
19 epidemiology in RRT patients. The urgent need for a 
better understanding of the epidemic in RRT patients was 
immediately evident, and therefore we designed a survey of 
the Nephrology centers in Italy, aimed to capture the main 
features, impact and geographical distribution of SARS-
CoV-2 spread in over 60,000 prevalent RRT patients during 
the exponential phase of the COVID-19 pandemic in Italy. 
We also sought to explore whether RRT modality-specific 
risks exist for SARS-CoV-2 infection and its consequences.
Methods
Survey oversight and design
On March 24th the Italian Society of Nephrology (SIN) 
Board of Directors constituted a task force and research 
group (The SIN COVID-19 Research Group) to promote 
and coordinate, at the national level, epidemiologic studies 
on the impact of COVID-19 pandemic on Italian Nephrology 
centers and patients.
As a first initiative to define the impact of the pandemic, 
the research group designed a fast-response cross-sectional 
survey. Such design was chosen because it allows to gather 
data in a narrow time interval and to assemble large amounts 
of information on a pre-defined number of items, thereby 
ensuring adequate statistical power and low margin of error. 
The sampling strategy was based on a convenience sample 
made of nephrology centers, the primary sampling units 
(PSU), listed in the DialMap database [16] with implicit 
aggregation of prevalent RRT patients within each PSU 
[17–19].
Instrument and key measures
All centers were invited to complete a short electronic 
questionnaire, an instrument designed to obtain 17 key 
information about patient, workforce and facilities during 
the exponential phase of COVID-19 pandemic. The 
questionnaire was internally developed by consensus, and 
explores five domains: (1) center characteristics (2) test 
positivity by treatment modality, (3) outcome by treatment 
modality, (4) preventive measures adopted, (5) policies for 
SARS-Cov-2 testing.
After an initial pilot study [19] in selected centers [20], 
the final version of the survey questionnaire was approved 
by SIN Board of Directors and sent by e-mail on April 9th 
2020. The survey deadline date was set for April 23rd 2020. 
All centers were instructed to input cumulative counts and 
define the actions taken since February 24th 2020. The study 
flow-chart and a copy of the questionnaire can be found in 
the supplementary material (Online Resource 1—Figure S3 
and Survey Questionnaire).
Laboratory testing
In all centers positive cases were identified using a reverse 
transcriptase–polymerase chain reaction (RT-PCR) test 
on samples obtained from the upper respiratory tract by 
nasopharyngeal or oropharyngeal swab. All samples were 
processed in regional certified laboratories according to 
procedures specified by the ISS Working Group Diagnostics 
and Microbiological Surveillance of COVID-19 [21].
Data acquisition and statistical analysis
For database handling and analysis, we used Microsoft 
 Excel® (Microsoft, WA, USA) and STATA version 15 
(StataCorp LLC, TX, USA).
To evaluate the quality and precision of the survey we 
calculated the response rate (the ratio of respondents to 
non-respondents) and the margin of error (the maximum 
expected difference between true population parameters and 
survey estimates) [18].
Test positive rates, by treatment modality and overall, 
were estimated using the number of positive cases as 
numerator and the number of patients as denominator. To 
calculate fatality rates we divided the number of deaths in 
persons who tested positive for SARS-CoV-2 by the number 
of SARS-CoV-2 cases, in keeping with the report of Italian 
National Institute of Health [3]. Confidence intervals for 
rates and proportions were calculated using the exact method 
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[22]. Poisson regression models were used to explore the 
association between case counts with region and latitude 
[23].
Geospatial analysis
Geographical information system (GIS) technology was 
used to manage geographic data.
A spatial database was created, with GIS layers of 
administrative units (regions and provinces) using the 
Istituto Nazionale di Statistica (ISTAT) shapefiles [24] and 
the SIN COVID-19 survey observations. A series of GIS-
supported procedures were implemented to geocode and 
aggregate data in the corresponding regions. Geospatial 
mapping, in choropleth style maps, was conducted using R 
Software Ver 3.6.3 (R Foundation for Statistical Computing, 
Vienna, Austria) with centers and RRT patients grouped at 
the region level [25].
Results
Centers
On April 9th 2020, all nephrology centers (n = 454) listed 
in the DialMap database [16] were invited to complete the 
electronic questionnaire. By the deadline date (April 23rd 
2020) 365 centers responded (80.4% response rate; 2.3% 
margin of error). The national distribution of participating 
centers is shown in the left panel of Fig. 1.
Preventive measures were adopted by all surveyed centers 
using personal protective equipment (PPE) and gloves for all 
patients and staff. Diagnostic testing policies varied across 
centers (Online Resource 1—Figure S1). The surveyed 
centers adopted a “test-all” policy more frequently for health 
care professional (30%) than for patients (16%; p < 0.001 
for the proportions difference). Conversely, patients were 
more likely to be tested than health-care professionals if 
symptomatic (58% vs. 42% respectively; p < 0.001 for the 
proportions difference). All surveyed centers did in person 
triage and modified access policies, while 227 centers, out 
of 365, systematically contacted patients (telephone triage) 
during the interdialytic interval. The vast majority of the 
centers (321/365; 88%) modified transport policies, using 
individual transport for suspected and/or confirmed cases 
in HD patients.
SARS‑Cov‑2 positive cases
The survey population included 30,821 hemodialysis 
(HD), 4139 peritoneal dialysis (PD), and 25,481 kidney 
transplant (Tx) patients, totaling 60,441 RRT patients 
(Fig.  1, right panel). There were 1368 SARS-CoV-2 
positive cases out of the 60,441 RRT patients surveyed 
(Fig. 2) with an overall rate of 2.26% (95% CI 2.14–2.39). 
There were significant differences (p < 0.001) according 
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Fig. 1  Choropleth map of the regional distribution of the 365 surveyed centers (left panel) and the 60,441 surveyed patients on renal replace-
ment therapy (RRT) (right panel)
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of positive cases was higher in HD (1093/30,821) than 
PD (57/4139) and Tx (218/25,481) respectively. The rate 
of positive cases exhibited substantial and significant 
heterogeneity along the latitude gradient (p < 0.001). 
In RRT patients the highest rate was in the north-west 
(4.39% [95% CI 4.11–4.68]), followed by the north-east 
(2.06% [1.79–2.36]), the center (0.91% [0.75–1.09]), the 
main islands (0.67% [0.47–0.93]), and the south (0.59% 
[0.45–0.75]). At finer level of geographical aggregation, 
significant heterogeneity (p < 0.001) persisted for all 
treatment modalities (Fig. 3).
Hemodialysis
In the north-west regions SARS-CoV-2 positivity rates 
in HD were higher than the national average (7.65% vs. 
3.55%; p < 0.001) but with substantial heterogeneity 
(Table 2; Fig. 3 panel A). Interestingly, north-east regions 
had lower rates than the north-west ones (3.30% vs. 7.65%; 
p < 0.001). In central Italy SARS-CoV-2 positivity rate 
was, on average, 1.39% (95% CI 1.12–1.71) but rates 
higher than expected were observed in Toscana (3.42% 
[95% CI 2.27–4.94]) and Marche (2.50% [95% CI 
1.63–3.66]). Starting from Umbria down south, and across 
the main islands, rates were generally lower than 1% with 
two notable extremes: Calabria with no SARS-CoV-2 
positive cases, and Abruzzo with the highest positivity 
rate (4.67% [95% CI 2.62–7.71]).
Peritoneal dialysis
Compared to HD, SARS-CoV-2 positive cases were less 
frequent among PD patients (1.38% vs 3.55%; p < 0.001; 
Table 3; Fig. 3 panel B) with 57 total cases, out of which 
two thirds were observed in four regions: Lombardia (17), 
Veneto (8), Piemonte (7) and Marche (6). In six regions no 
cases were registered.
Fig. 2  Map of SARS-CoV-2 
positive cases in the 60,441 sur-
veyed renal replacement therapy 
(RRT) patients observed from 
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Table 1  Exposed patients, SARS-CoV-2 positive cases and incidence 
rate by treatment modality and overall
HD hemodialysis, PD peritoneal dialysis, Tx transplant, RRT renal 
replacement therapy, IR incidence rate
Treatment 
modality
Exposed patients SARS-CoV-2 
positive cases
IR per 100 95% CI
HD 30,821 1093 3.55 3.34 3.76
PD 4139 57 1.38 1.04 1.78
Tx 25,481 218 0.86 0.75 0.98
RRT 60,441 1368 2.26 2.14 2.39
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Kidney transplant
The north-to-south geographical gradient of SARS-CoV-2 
positive cases was confirmed also for Tx patients (Table 4; 
Fig. 3 panel C), even though the overall rate (0.86% [95% 
CI 0.76–0.99]) was the lowest observed among treatment 
modalities. About three-quarters of the 218 SARS-Cov-2 
positive Tx patients were observed in two regions: Lombar-
dia (131) and Piemonte (31). In five regions no cases were 
registered.
Case fatality
There were 449 deaths among 1368 SARS-CoV-2 positive 
RRT patients, with an overall case fatality rate (CFR) of 
32.82% (95% CI 29.9–36.0). However, there were substantial 
A) Hemodialysis B) Peritoneal Dialysis C) Transplant
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Fig. 3  Map of the regional distribution of SARS-CoV-2 infection rates by renal replacement modality: a hemodialysis (HD); b peritoneal dialy-
sis (PD); c transplant (Tx)
Table 2  SARS-CoV-2 incidence rates in hemodialysis patients by 
geographical macro-region and nationally
HD hemodialysis, IR incidence rate
Macro-region Exposed HD 
patients
IR per 100 95% CI
North-West 9717 7.65 7.11 8.22
North-East 5242 3.30 2.83 3.83
Center 6462 1.39 1.12 1.71
South 5567 0.97 0.73 1.27
Main Islands 3833 0.86 0.59 1.21
Italy 30,821 3.55 3.34 3.76
Table 3  SARS-CoV-2 incidence rates in peritoneal dialysis patients 
by geographical macro-region and nationally
PD peritoneal dialysis, IR incidence rate
Macro-region Exposed PD 
patients
IR per 100 95% CI
North-West 1281 2.26 1.52 3.25
North-East 952 1.58 0.88 2.60
Center 791 1.14 0.52 2.16
South 626 0.32 0.04 1.15
Main Islands 489 0.41 0.05 1.48
Italy 4139 1.38 1.04 1.78
Table 4  SARS-CoV-2 incidence rates in transplant patients by geo-
graphical macro-region and nationally
Tx transplant patients, IR incidence rate
Macro-region Exposed Tx 
patients
IR per 100 95% CI
North-West 10,513 1.64 1.40 1.90
North-East 4014 0.55 0.34 0.83
Center 5417 0.29 0.17 0.48
South 4495 0.16 0.06 0.32
Main Islands 1042 0.10 0.00 0.53
Italy 25,481 0.86 0.75 0.98
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and significant differences (Table  5) among treatment 
modalities (p < 0.001). Specifically, CFR was 33.76% in HD, 
45.61% in PD, and 24.77% in Tx patients.
Hemodialysis
Out of 1069 SARS-CoV-2 positive HD, 369 died.
The geographical distribution of fatality rates among 
SARS-CoV-2 positive HD patients (Fig. 4) was not influ-
enced by latitude (p = 0.653) or region-specific effect 
(p = 0.243). Restricting the analysis to the regions where 
at least 10 deaths were observed, accounting for 333 fatal 
cases (86.6%), the rates remained well above 25% (Online 
Resource 1—Table S1). Only two regions reported no deaths 
among SARS-CoV-2 positive HD patients.
Peritoneal dialysis
Out of 57 SARS-CoV-2 positive PD patients, 26 died 
(Table 5). Although on sparse counts (Online Resource 1—
Table S2), this was the highest national fatality rate (CFR 
45.61% [95% CI 29.80–66.83]).
Kidney transplant
Out of 218 SARS-CoV-2 positive Tx patients 54 died with a 
24.77% fatality rate, the lowest among treatment modalities 
(Table 5). The highest toll was paid by Lombardia (26) and 
Piemonte (13), collectively 39 out of 54 total deaths (Online 
Resource 1—Table S3).
Discussion
In the last few months, Italian nephrologists have been 
contrasting the overwhelming COVID-19 pandemic with 
all available means and strategies, including stringent 
containment measures, extensive diagnostic testing, 
especially in high risk patients, and by sharing the latest 
information transparently and promptly [8, 10, 26]. 
Table 5  Number of deaths and fatality rates in 1368 SARS-CoV-2 
positive patients by treatment modality and overall








HD 1093 369 33.76 30.43 37.42
PD 57 26 45.61 29.80 66.83
Tx 218 54 24.77 18.61 32.32
RRT 1368 449 32.82 29.86 36.00
Fig. 4  Regional map of case 
fatality rates (CFR) in SARS-
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The impact and burden of COVID-19 pandemic on the 
Nephrology community in Italy was indeed a “life-changing 
experience” [27]. Recommendations to contain the spread 
of infection in RRT patients have been quickly posted 
[28–30], but little is known on the outcomes at the country 
and regional levels, where the pandemic appears to spread 
with varying degrees of intensity [11, 12, 14, 31].
The Italian Society of Nephrology COVID-19 Survey is 
the first initiative fostering a national research collaboration 
on the pandemic impact on RRT patients and centers.
Overall, the survey shows that a significant proportion 
of RRT patients are SARS-Cov-2 positive, in settings 
where most of the tests were done in symptomatic patients. 
Positivity rates showed significant heterogeneity among 
regions (p < 0.001) as well as along the country latitude 
gradient (p < 0.001). Such heterogeneity might depend upon 
several factors including the local rate of infection spread 
and burden, the type and effectiveness of containment 
measures, and the testing strategies adopted. Besides, the 
scattering of local outbreaks along the latitude, temperature, 
and humidity gradients is fairly consistent with the spread of 
seasonal respiratory virus infections [32, 33]. Nonetheless, 
our descriptive findings deserve further investigation, 
since, if causal links will be established, they might have 
significant impact on future containment and lockdown 
policies.
Fewer PD and Tx patients tested positive for SARS-
CoV-2. Unlike HD, PD and Tx patients refer to nephrology 
centers for scheduled visits, typically a few weeks apart, 
while continuing treatment at home, thus limiting the 
exposure [11, 12, 15]. Moreover, home treated patients, 
as well as their caregivers, are usually well trained and 
acquainted with effective measures to reduce infection risk. 
Incidentally, telemedicine and remote consulting [28, 34] 
might have further contributed to reduce the risks in these 
cases.
The fatality rate was impressively high: 34% among 
HD patients with no substantial differences across and 
along the country. Such figure is 2.5 times higher than 
the 13.3% overall case-fatality rate estimated in Italy as 
of April 23rd [5]. Interestingly, even though the absolute 
number of deaths in central and southern regions was lower 
than in northern Italy, the regional rates were larger than 
expected. The huge death toll paid by HD patients in the 
first 2 months of the pandemic is likely due to the inherent 
clinical characteristics of HD patients such as advanced age, 
major comorbidities and frailty status. Of note, fatality rates 
remained substantially higher than expected, even though 
with wide confidence intervals, also among PD and Tx 
patients (45% and 25% respectively). With all due caution, 
our findings collectively suggest that even at low infection 
rates, as observed in PD and Tx, fatal outcomes are common 
among SARS-Cov-2 positive RRT patients.
Finally, while hospitals and facilities were tackling an 
overwhelming pandemic, Nephrologists had also to treat 
COVID-19 related acute kidney injury (AKI) [35, 36]. 
The surveyed centers reported 607 AKI cases requiring 
RRT in intensive care units (Online Resource—Figure S2). 
The prompt response of nephrology teams in emergency 
settings must be recognized [37], and we believe that the 
timely recommendations endorsed by the Italian Society 
of Nephrology [26] provided a comprehensive and 
continuously updated guidance.
The present survey has the strength of covering the 
majority of the RRT centers and patients in a nation that 
was heavily confronted by the COVID-19 pandemic, but 
also has some limitations. The findings should be interpreted 
judiciously because the centers database, on which the study 
was built, is primarily used for administrative management 
rather than research. Given the limited resources available 
and the time-sensitivity of the COVID-19 pandemic, we 
adopted a non-probability sampling strategy. Nonetheless, 
since the survey response rate was over 80%, with a small 
margin of error (2.3% at the 95% confidence level), and 
covered over 90% of the country territory, the estimates can 
be considered reliable and precise with low uncertainty.
Conclusions
Nationwide and international collaboration, such as 
the Italian Society of Nephrology COVID-19 Research 
project, are extremely important to support the 
development of effective strategies to reduce the burden 
of severe and potentially fatal disease among RRT patients 
[8, 28]. The Italian Society of Nephrology COVID-
19 survey confirms and extends previous preliminary 
observations suggesting that RRT patients, especially 
those on HD, are at increased risk of developing severe 
SARS-Cov-2 infections. Conversely, home treated patients 
are at lower risk of being infected. While positivity rates 
showed a significant latitude and region effect, in keeping 
with what was observed in the general population, these 
factors did not affect death rates, suggesting that fatality is 
inherently linked to RRT status and related comorbidities. 
Our f indings support and reinforce the current 
recommendations of the Italian Society of Nephrology 
[28, 31] on prompt, effective and meticulous care of RRT 
patients, to reduce the risk of SARS-Cov-2 infection and 
its adverse prognostic implications [12–14, 28, 30, 31].
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Appendix
Italian Society of Nephrology COVID‑19 
Research Group
1. Italian Society of Nephrology Board of Directors
  Giuliano Brunori, Piergiorgio Messa, Filippo Aucella, 
Manuela Bosco, Fabio Malberti, Marcora Mandreoli, 
Sandro Mazzaferro, Ezio Movilli, Giuseppe Quintaliani, 
Maura Ravera, Mario Salomone, Domenico Santoro
2. DialMap
  Maurizio Postorino, Aurelio Limido
3. Participating Centers and Investigators by Region:
Abruzzo:
  Chieti (M. Bonomini); Ortona-Guardagriele (A. 
Stingone); Lanciano Casoli Atessa (M. Maccarone); PO 
Atri (E. Di Loreto); Giulianova (L. Stacchiotti); Teramo 
(R. Malandra);
  Calabria: Area Ionica Soverato-Catanzaro (S. 
Chiarella); Lamezia Terme (F. D’Agostino); AOU Mater 
Domini—Catanzaro (G. Fuiano); PO Rossano—Rossano 
(CS) (L. Nicodemo); Osp. Annunziata Cosenza—Rete 
emodialitica territoriale—Asp di Cosenza—Cosenza 
(R. Bonofiglio); Crotone (S. Greco); Reggio Calabra 
(F. Mallamaci); Scilla (E. Barreca); Melito Porto Salvo 
(C. Caserta); Taurianova (V. Bruzzese); Serra San 
Bruno-Soriano Calabro (D. Galati); Vibo Valentia (D. 
Tramontana);
  Campania: AO Moscati Avellino (M. Viscione); 
Dyalisis—Capodicasa (L. Chiuchiolo); Solofra (S. 
Tuccillo); Emodialisi Irpina Grottaminarda (M. 
Sepe); Osp. Ariano Irpino (F. Vitale); PO Santa Maria 
della Pietà—Nola (E. Ciriana); Dialisi Alra Irpinia 
Calitri (D. Santoro); AO G. Rummo—Benevento (V. 
Martignetti); AORN Caserta—Caserta (D. Caserta); 
Adem Marcianise—Marcianise (A. Stizzo); Helios 
Capua (A. Romano); SSD ASL Caserta—San Felice 
a Cancello (G. Iulianiello); Emodialisi Ludial—Castel 
Volturno (E. Cascone); Polisan San Nicola La Strada (P. 
Minicone); Emodialisi Cedial Santa Maria Capua Vetere 
(D. Chiricone); Emodialisi Luna Teano (G. Delgado); 
Vairano Patenora Caserta (A. Barbato); DIALCA 
SRL Caiazzo (S. Celentano); Cedial Sessa Aurunca 
(I. Molfino); PO Piedimonte Matese (S. Coppola); 
Iatreion Caserta (I. Raiola); Diam Nefrocenter—
Maddaloni (M. Abategiovanni); Centro Atellano—
Orta di Atella (CE) (S. Borrelli); Renart—Casagiove 
(C. Margherita); Nefrodial—Aversa (F. Bruno); Cedial 
Srl—San Cipriano D’Aversa (M. Ida); Alma Center—
Mariglianella (E. Aliperti); CGA—Giugliano in 
Campania (D. Potito); CMO—Gragnano (G. Cuomo); 
Ambulatorio Emodialisi—Mugnano di Napoli (M. 
De Luca); Seironos—Sorrento (M. Merola); DIAL 
3—Arzano (NA) (C. Botta); Nephrocare—Napoli (G. 
Garofalo); AO Cardarelli—Napoli (P. Alinei); Osp. Del 
Mare—Napoli (C. Paglionico); Dialgest—Casoria (M. 
Roano); Gruppo Dialisi Campano—Frattamaggiore (S. 
Vitale); Centro Delta—Boscoreale (R. Ierardi); CNP 
Frattamaggiore—Frattamaggiore (v. Fimiani); PO 
Santa Maria degli Incurabili Univ. Vanvitelli—Napoli 
(G. Conte); Ospedale Pellegrini—Napoli (G. Di Natale); 
Emodialisi Vesuviana—San Giuseppe Vesuviano (M. 
Romano); Gestione Servizi Emodialisi—Pozzuoli (V. Di 
Marino); Dial Cast Srl—Santa Maria La Carità (NA) 
(A. Scafarto); Villa S. Andrea—Napoli (S. Meccariello); 
AO Santobono Pausilipon—Napoli (C. Pecoraro); 
Cendial—Acerra (E. Di Stazio); Ischia (E. Di Meglio); 
Emodialisi EURODIAL—Napoli (A. Cuomo); Sean 
Srl—Aversa (B. Maresca); S. Pio X—Afragola (E. 
Rotaia); Nefrologia e Dialisi Univ. Vanvitelli—Napoli 
(G. Capasso); San Leonardo ASL NA3 SUD (M. 
Auricchio); D. Cotugno AORN dei Colli—Napoli (C. 
Pluvio); Kidney—Casavatore (L. Maddalena); CMM—
Cava dei Tirreni (A. De Maio); AO Ruggi Mercato San 
Severino—Ospedale Ruggi Salerno (G. Palladino); PO 
Polla (F. Buono); Eboli (G. Gigliotti);
  Emilia Romagna: Imola (M. Mandreoli); Malpighi 
e S. Orsola—Bologna (E. Mancini. G. La Manna); 
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